Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Abcellera Biologics Inc (ABCL)

Abcellera Biologics Inc (ABCL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
AbCellera Biologics (ABCL) Q4 2023 Earnings Call Transcript

ABCL earnings call for the period ending December 31, 2023.

ABCL : 4.03 (+4.68%)
4 Magnificent Healthcare Stocks to Buy in 2024 and Beyond

Healthcare stocks have underperformed in 2023, but that is expected to change this year.

CNC : 74.81 (+0.65%)
HALO : 39.91 (+0.23%)
ABCL : 4.03 (+4.68%)
HUM : 320.54 (-0.14%)
3 Growth Stocks That Could Go Parabolic in 2024

These innovation-oriented companies could take flight this year.

ABCL : 4.03 (+4.68%)
CERS : 1.6200 (-7.95%)
TSHA : 2.57 (-0.39%)
AbCellera Biologics (ABCL) Q3 2023 Earnings Call Transcript

ABCL earnings call for the period ending September 30, 2023.

ABCL : 4.03 (+4.68%)
Argenx's 28% Surge & Promising Product Propel Investor Confidence

Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.

ARGX : 388.20 (-1.33%)
ABBV : 163.79 (+1.85%)
ABCL : 4.03 (+4.68%)
ALNY : 152.33 (+1.34%)
AMGN : 311.29 (+11.82%)
ANAB : 26.58 (+0.91%)
AZN : 76.35 (+0.73%)
BMY : 43.99 (+0.66%)
INCY : 53.76 (+1.26%)
REGN : 957.00 (+2.07%)
VIE : 53.01 (unch)
AbCellera Biologics (ABCL) Q2 2023 Earnings Call Transcript

ABCL earnings call for the period ending June 30, 2023.

ABCL : 4.03 (+4.68%)
AbCellera Biologics (ABCL) Q1 2023 Earnings Call Transcript

ABCL earnings call for the period ending March 31, 2023.

ABCL : 4.03 (+4.68%)
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Tops Revenue Estimates

AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of -16.67% and 6.76%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

ABCL : 4.03 (+4.68%)
PIRS : 11.08 (-1.42%)
AbCellera Reports Q1 2023 Business Results

AbCellera (Nasdaq: ABCL) today announced financial results for the first quarter of 2023. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.

ABCL : 4.03 (+4.68%)
How AI Is Revolutionizing Tech, and Why You Should Invest in These Leading Companies

Check out these compelling opportunities.

ABBV : 163.79 (+1.85%)
ABCL : 4.03 (+4.68%)
ISRG : 381.36 (+0.98%)
MSFT : 406.66 (+2.22%)
AMZN : 186.21 (+0.81%)
NET : 74.40 (-16.38%)

Barchart Exclusives

2 Small-Cap Stocks With 40% to 60% Upside
Wall Street believes these two growth stocks will soar, driven by the demand for their products. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar